[
    [
        {
            "time": "",
            "original_text": "华东医药：瑞格列奈片项目目前已暂停推进 项目问题",
            "features": {
                "keywords": [
                    "瑞格列奈片",
                    "暂停推进",
                    "项目问题"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "制药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "华东医药：瑞格列奈片项目目前已暂停推进 项目问题",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-11-27",
            "original_text": "华东医药：公司收到美国FDA批准注射用达托霉素的时间为2021年11月27日",
            "features": {
                "keywords": [
                    "FDA",
                    "批准",
                    "注射用达托霉素"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "制药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华东医药：公司收到美国FDA批准注射用达托霉素的时间为2021年11月27日",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 3,
                "Headline_Structure": 6,
                "Source_Recency": 2
            }
        },
        {
            "time": "",
            "original_text": "华东医药：HD118因临床进度及公司研发调整的原因，已不再推进",
            "features": {
                "keywords": [
                    "HD118",
                    "临床进度",
                    "研发调整",
                    "不再推进"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "制药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "华东医药：HD118因临床进度及公司研发调整的原因，已不再推进",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "华东医药：公司递交的利拉鲁肽注射液糖尿病适应症的上市申请已提交，目前正在进行审评",
            "features": {
                "keywords": [
                    "利拉鲁肽注射液",
                    "糖尿病",
                    "上市申请",
                    "审评"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "制药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华东医药：公司递交的利拉鲁肽注射液糖尿病适应症的上市申请已提交，目前正在进行审评",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2022",
            "original_text": "华东医药：DR10624为公司控股子公司浙江道尔生物科技有限公司在研的GLP-1R/GCGR/FGF21靶点的多重激动剂，可用于2型糖尿病、肥胖和非酒精性脂肪性肝炎（NASH）等疾病的治疗，目前在准备2022年海外启动1期临床试验和中国pre-IND申请",
            "features": {
                "keywords": [
                    "DR10624",
                    "GLP-1R/GCGR/FGF21",
                    "多重激动剂",
                    "2型糖尿病",
                    "肥胖",
                    "NASH",
                    "1期临床试验",
                    "pre-IND申请"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "制药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华东医药：DR10624为公司控股子公司浙江道尔生物科技有限公司在研的GLP-1R/GCGR/FGF21靶点的多重激动剂，可用于2型糖尿病、肥胖和非酒精性脂肪性肝炎（NASH）等疾病的治疗，目前在准备2022年海外启动1期临床试验和中国pre-IND申请",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2022",
            "original_text": "华东医药：目前在准备2022年海外启动1期临床试验和中国pre-IND申请",
            "features": {
                "keywords": [
                    "1期临床试验",
                    "pre-IND申请",
                    "海外启动"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "制药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华东医药：目前在准备2022年海外启动1期临床试验和中国pre-IND申请",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        }
    ]
]